Medpace stock falls 2.07 percent as CEO sale surfaces

Medpace stock fell 2.07 percent to USD 617.15 on Nasdaq on September 23, 2026, giving investors a fresh market signal after the company reported second-quarter revenue growth of 17.2 percent. The latest insider filing also disclosed the sale of 21,883 shares by Medpace's chief executive, according to MarketBeat on September 23, 2026.

Revenue growth stays in double digits

Medpace reported USD 707.3 million in revenue for Q2 2026, compared with USD 603.3 million in Q2 2025, according to Business Wire. That 17.2 percent increase gives the clinical research organization a measurable operating cushion, even as the share price remains below its September 23 high of USD 637.64.

Quarterly diluted EPS was USD 4.25, up from USD 3.10 in the comparable period, while MarketBeat reported a consensus estimate of USD 3.98. The USD 0.27 beat matters because earnings growth is currently doing more of the valuation work than the daily price move.

Analyst target trails the stock

Jefferies reiterated a Hold rating and a USD 560.00 price target on September 14, 2026, as reported by Investing.com. The target sits USD 57.15 below the September 23 quote, while MarketBeat cited a broader consensus target of USD 595.20.

Medpace also set fiscal 2026 EPS guidance at USD 17.25 to USD 17.95, according to MarketBeat. The range provides a concrete benchmark for the October 21, 2026 reporting date announced by Business Wire.

Stock remains below yearly high

Medpace's September 23 price of USD 617.15 was USD 60.75 below its 52-week high of USD 677.90 and USD 244.15 above its 52-week low of USD 373.00. Market capitalization stood at USD 17,225,705,655 on the same date, placing the clinical research business among the larger publicly traded contract research organizations.